Form 4: AN2 Therapeutics CFO Sells Shares for Tax Obligations

AN2 Therapeutics' Chief Financial Officer, Lucy Day, sold shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Summary

• Lucy Day, Chief Financial Officer of AN2 Therapeutics, Inc. (ANTX), reported sales of common stock.
• On January 5, 2026, 3,295 shares were sold at a price of $1.003 per share.
• On January 6, 2026, an additional 5,512 shares were sold at a price of $1.012 per share.
• These sales were executed to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on January 1, 2026.
• Following these transactions, Lucy Day beneficially owns 75,363 shares of common stock.
• The beneficial ownership includes 27,500 RSUs vesting annually over four years from January 1, 2024, and 46,500 RSUs vesting annually over four years from January 1, 2025.
• The reported total beneficial ownership also reflects the purchase of 5,000 shares under the Issuer's Employee Stock Purchase Plan on September 30, 2025.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions for tax withholding purposes, which is a neutral event and does not reflect discretionary buying or selling based on company performance or outlook.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates continued compensation and retention of the Chief Financial Officer.
• The purchase of 5,000 shares under the Employee Stock Purchase Plan (ESPP) on September 30, 2025, demonstrates ongoing participation in the company's equity program.

Negatives

• A reduction in direct beneficial ownership by a key executive, totaling 8,807 shares, occurred through sales.

Future Outlook

The Chief Financial Officer has 27,500 Restricted Stock Units (RSUs) that will vest annually over four years from January 1, 2024, and an additional 46,500 RSUs that will vest annually over four years from January 1, 2025, contingent on continued service to the company.

Industry Context

This Form 4 filing reports a routine insider transaction for tax purposes, which is a common occurrence across industries when executive compensation includes Restricted Stock Units (RSUs). It does not provide broader industry-specific insights.

Stakeholder Impact

• Shareholders: Experience a minor, non-discretionary reduction in direct insider ownership, which is a common event for RSU vesting and tax obligations.
• Employees (specifically the CFO): Benefit from the vesting of RSUs as part of their compensation package.

Next Steps

• Continued vesting of 27,500 RSUs annually over four years from January 1, 2024.
• Continued vesting of 46,500 RSUs annually over four years from January 1, 2025.

Key Dates

Keywords

AN2 Therapeutics, ANTX, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, Chief Financial Officer